Integrum AB Class B (INTEG.B) AI Stock Analysis

• Market Cap: kr432.02M
• Dividend Yield: N/A
• Average Volume (3M): 38.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.02
• Revenue Growth: -12.50%
• EPS Growth: -783.92%
• Country: SE
• Employees: 36
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.44
• Shares Outstanding: 20,694,328
• 10 Day Avg. Volume: 18,879
• 30 Day Avg. Volume: 38,968
• PEG Ratio: 0.16
• Price to Book (P/B): 3.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: kr22.00 ▲(10.00%Upside)

The stock's score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. Despite strong technical indicators suggesting bullish momentum, valuation concerns due to a negative P/E ratio weigh heavily. The absence of earnings call and corporate event data limits additional insights.

Integrum AB Class B Business Overview & Revenue Model

Company Description

Integrum AB Class B (INTEG.B) is a Swedish company specializing in developing and marketing innovative solutions for orthopedic and reconstructive surgery, focused primarily on osseointegration technology. The company is renowned for its OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) Implant System, which is designed to improve the quality of life for amputees by providing a direct connection between the prosthesis and the bone, enhancing mobility and comfort.

How the Company Makes Money

Integrum AB generates revenue primarily through the sale of its OPRA Implant System and related services. The company earns money by selling these advanced prosthetic solutions to healthcare providers and directly to patients globally. Additionally, Integrum engages in partnerships with medical institutions for research and development, which may also contribute to its revenue. The company leverages its expertise in osseointegration technology to expand its market presence and drive sales growth in the orthopedic and reconstructive surgery sectors.

Integrum AB Class B Financial Statement Overview

Summary

Integrum AB Class B faces profitability and cash flow challenges despite a strong balance sheet. The income statement shows fluctuating revenues and negative profit margins, while cash flow is strained with negative free cash flow growth. Strategic focus is needed to stabilize growth and improve operational cash generation.

Income Statement

Integrum AB Class B has experienced fluctuating revenues with a notable decline in the TTM period, indicating potential instability. The gross profit margin remains relatively strong, but negative EBIT and net profit margins highlight ongoing profitability challenges. Revenue growth has been inconsistent, suggesting a need for strategic adjustments to stabilize growth.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, suggesting a solid financial foundation. However, the debt-to-equity ratio is low, indicating limited leverage use, which could be a double-edged sword in terms of growth potential. Return on equity has been negative in recent years due to ongoing net losses, raising concerns about shareholder value.

Cash Flow

Cash flow analysis reveals negative free cash flow growth and a challenging operating cash flow scenario, which could strain liquidity. Despite this, financing activities have provided short-term cash infusions. The company needs to improve cash generation from operations to ensure long-term financial health.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	90.01M	104.12M	74.27M	55.72M	43.09M	26.75M
Gross Profit	54.83M	91.26M	60.84M	46.56M	34.89M	21.37M
EBITDA	-22.34M	8.76M	-20.24M	2.60M	-1.59M	-14.98M
Net Income	-19.55M	4.03M	-16.18M	21.27M	-2.14M	-15.69M
Balance Sheet
Total Assets	180.29M	164.86M	165.17M	180.44M	37.21M	32.20M
Cash, Cash Equivalents and Short-Term Investments	14.65M	16.90M	41.92M	75.34M	7.66M	13.06M
Total Debt	5.25M	6.42M	7.92M	580.89K	485.92K	723.80K
Total Liabilities	17.69M	22.07M	21.64M	20.70M	12.91M	8.47M
Stockholders Equity	162.60M	142.79M	143.53M	159.74M	24.29M	23.73M
Cash Flow
Free Cash Flow	-58.94M	-24.37M	-36.50M	-49.55M	-7.47M	-19.06M
Operating Cash Flow	-44.88M	-12.74M	-25.10M	-20.28M	-5.76M	-18.72M
Investing Cash Flow	-14.07M	-11.63M	-11.40M	-29.27M	-1.71M	-343.68K
Financing Cash Flow	45.23M	-648.54K	3.08M	117.23M	2.06M	21.51M

Integrum AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Positive. The current price of 20 is below the 20-day moving average (MA) of 20.53, above the 50-day MA of 17.86, and above the 200-day MA of 19.51, indicating a neutral trend. The MACD of 0.44 indicates Positive momentum. The RSI at 53.44 is Neutral, neither overbought nor oversold. The STOCH value of 40.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:INTEG.B.

Integrum AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INTEG.B	53 Neutral	kr432.02M	―	-19.17%	―	-12.50%	-783.92%
Sector *	50 Neutral	kr5.46B	12.72	-80.61%	5.07%	37.36%	27.71%
BRAIN	50 Neutral	kr396.30M	―	-33.54%	―	72.05%	33.68%
ACARIX	46 Neutral	kr361.14M	―	-88.97%	―	-0.61%	54.19%
MNTC	45 Neutral	kr377.14M	―	-17.16%	―	17.75%	18.05%
MNTC	45 Neutral	kr377.14M	―	-17.16%	―	17.75%	18.05%
DOXA	43 Neutral	kr547.64M	―	-48.55%	―	-2.22%	-295.24%
DOXA	43 Neutral	kr547.64M	―	-48.55%	―	-2.22%	-295.24%
QLINEA	43 Neutral	€477.73M	―	-159.24%	―	-22.50%	76.74%
QLINEA	43 Neutral	€477.73M	―	-159.24%	―	-22.50%	76.74%